[1. Ogdie, A., Schwartzman, S. & Husni, M.E. (2015). Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol, 27(2), 118-126. doi: 10.1097/BOR.0000000000000152.10.1097/BOR.000000000000015225603040]Search in Google Scholar
[2. Baker, J.F., Krishnan, E., Chen, L. & Schumacher, H.R. (2005). Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med, 118(8), 816-826. doi: 10.1016/j.amjmed.2005.03.043.10.1016/j.amjmed.2005.03.04316084170]Search in Google Scholar
[3. Bruce, I.N., Schentag, C.T. & Gladman, D.D. (2000). Hyperuricemia in psoriatic arthritis: prevalence and associated features. J Clin Rheumatol, 6(1), 6-9..10.1097/00124743-200002000-00001]Search in Google Scholar
[4. Peluso, R., Iervolino, S., Vitiello, M., Bruner, V., Lupoli, G. & Di Minno, M.N. (2015). Extra-articular manifestations in psoriatic arthritis patients. Clin Rheumatol, 34(4), 745-753. doi: 10.1007/s10067-014-2652-9.10.1007/s10067-014-2652-924803233]Search in Google Scholar
[5. Casals-Sanchez, J.L., Garcia De Yebenes Prous, M.J., Descalzo Gallego, M.A., Barrio Olmos, J.M., Carmona Ortells, L., Hernandez Garcia, C., & Grupo de Estudio em, A.R., II. (2012). Characteristics of patients with spondyloarthritis followed in rheumatology units in Spain. emAR II study. Reumatol Clin, 8(3), 107-113. doi: 10.1016/j.reuma.2012.01.006.10.1016/j.reuma.2012.01.00622465418]Search in Google Scholar
[6. Alenius, G.M., Stegmayr, B.G., & Dahlqvist, S.R. (2001). Renal abnormalities in a population of patients with psoriatic arthritis. Scand J Rheumatol, 30(5), 271-274.10.1080/03009740175318034511727841]Search in Google Scholar
[7. Ogdie, A., Schwartzman, S., Eder, L., Maharaj, A.B., Zisman, D., Raychaudhuri, S.P., Reddy, S.M. & Husni, E. (2014). Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations. J Rheumatol, 41(11), 2315-2322. doi: 10.3899/jrheum.140882.10.3899/jrheum.14088225362717]Search in Google Scholar
[8. Widemann, B.C. & Adamson, P.C. (2006). Understanding and managing methotrexate nephrotoxicity. Oncologist, 11(6), 694-703. doi: 10.1634/theoncologist.11-6-69410.1634/theoncologist.11-6-69416794248]Search in Google Scholar
[9. Dervisoglu, E., Akturk, A.S., Yildiz, K., Kiran, R. & Yilmaz, A. (2012). The spectrum of renal abnormalities in patients with psoriasis. Int Urol Nephrol, 44(2), 509-514. doi: 10.1007/s11255-011-9966-1.10.1007/s11255-011-9966-121505751]Search in Google Scholar
[10. Chiu, H.Y., Huang, H.L., Li, C.H., Yin, Y.J., Chen, H.A., Hsu, S.T., Lin, S.J., Tsai, T.F. & Ho, S.Y. (2015). Increased risk of glomerulonephritis and chronic kidney disease in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. Br J Dermatol, 173(1), 146-154. doi: 10.1111/bjd.1359910.1111/bjd.1359925511692]Search in Google Scholar
[11. Rodrigues, C.E., Vieira, W.P., Bortoluzzo, A.B., Goncalves, C.R., da Silva, J.A., Ximenes, A.C., Bertolo, M.B., Ribeiro, S.L., Keiserman, M., Menin, R., Skare, T.L., Carneiro, S., Azevedo, V.F., Albuquerque, E.N., Bianchi, W.A., Bonfiglioli, R., Campanholo, C., Carvalho, H.M., Costa, I.P., Duarte, A.P., Kohem, C.L., Leite, N.H., Lima, S.A., Meirelles, E.S., Pereira, I.A., Pinheiro, M.M., Polito, E., Resende, G.G., Rocha, F.A., Santiago, M.B., Sauma Mde, F., Valim, V. & Sampaio-Barros, P.D. (2012). Low prevalence of renal, cardiac, pulmonary, and neurological extra-articular clinical manifestations in spondyloarthritis: analysis of the Brazilian Registry of Spondyloarthritis. Rev Bras Reumatol, 52(3), 375-383..]Search in Google Scholar
[12. Feldman, S.R., Zhao, Y., Shi, L., Tran, M.H. & Lu, J. (2015). Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis. Arthritis Care Res (Hoboken), 67(5), 708-717. doi: 10.1002/acr.2249210.1002/acr.22492502958925303478]Search in Google Scholar
[13. Keith, D.S., Nichols, G.A., Gullion, C.M., Brown, J.B. & Smith, D.H. (2004). Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med, 164(6), 659-663. doi: 10.1001/archinte.164.6.659.10.1001/archinte.164.6.65915037495]Search in Google Scholar
[14. Foley, R.N., Murray, A.M., Li, S., Herzog, C.A., McBean, A.M., Eggers, P.W. & Collins, A.J. (2005). Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol, 16(2), 489-495. doi: 10.1681/ASN.2004030203.10.1681/ASN.200403020315590763]Search in Google Scholar
[15. National Kidney Foundation (2012). KDOQI clinical practice guidelines for glomerulonephritis Kidney Int.; 2(suppl 2):209-233]Search in Google Scholar
[16. Pana, C., Tuta, L., Hanzu-Pazara, L. & Suta, M. (2015) Association between inflammation and renal involvement in psoriatic arthritis Nephrol. Dial. Transplant. 30 (suppl 3): iii519]Search in Google Scholar
[17. Chi, C.C., Wang, J., Chen, Y.F., Wang, S.H., Chen, F.L. & Tung, T.H. (2015). Risk of incident chronic kidney disease and end-stage renal disease in patients with psoriasis: A nationwide population-based cohort study. J Dermatol Sci, 78(3), 232-238. doi: 10.1016/j.jdermsci.2015.03.01210.1016/j.jdermsci.2015.03.01225862150]Search in Google Scholar